IPO registrations (S-1, F-1) · Registrants
Old API Wind-down Ltd.
- SEC CIK
- 1660719 · filings on EDGAR ↗
- Name on the registration
- Aralez Pharmaceuticals Inc.
- Former names
- Aralez Pharmaceuticals Inc. (2015–2019)
- Registration
- Form S-1, first filed 2015-12-31, last 2016-01-22; 3 initial registrations, 6 amendments
- Outcome
- Declared effective 2016-02-05; withdrawal requested 2017-03-21
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- A1
- Business address
- 666 BURRARD STREET, Vancouver, A1 V6C 2X8
- EDGAR entity type
- operating
- Insiders and CEO pay
- Old API Wind-down Ltd. on the corporate pages
Offering terms
- Shares offered
- 4,800,000
- Listing
- Nasdaq under the symbol POZN
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Aralez Pharmaceuticals Inc. EXACT (CIK (EXACT))
- SEC filer: Aralez Pharmaceuticals Inc. EXACT (CIK (EXACT))
- Person page: John E Barnhardt Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
Filings 18
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2015-12-31 | S-1 | S-1 (registration) | Aralez Pharmaceuticals Inc. | 0001047469-15-009492 ↗ |
| 2015-12-31 | S-1 | S-1 (registration) | Aralez Pharmaceuticals Inc. | 0001047469-15-009493 ↗ |
| 2015-12-31 | S-1 | S-1 (registration) | Aralez Pharmaceuticals Inc. | 0001047469-15-009494 ↗ |
| 2016-01-08 | S-1/A | S-1/A (amendment) | Aralez Pharmaceuticals Inc. | 0001047469-16-009602 ↗ |
| 2016-01-08 | S-1/A | S-1/A (amendment) | Aralez Pharmaceuticals Inc. | 0001047469-16-009603 ↗ |
| 2016-01-08 | S-1/A | S-1/A (amendment) | Aralez Pharmaceuticals Inc. | 0001047469-16-009604 ↗ |
| 2016-01-22 | S-1/A | S-1/A (amendment) | Aralez Pharmaceuticals Inc. | 0001047469-16-009775 ↗ |
| 2016-01-22 | S-1/A | S-1/A (amendment) | Aralez Pharmaceuticals Inc. | 0001047469-16-009776 ↗ |
| 2016-01-22 | S-1/A | S-1/A (amendment) | Aralez Pharmaceuticals Inc. | 0001047469-16-009778 ↗ |
| 2016-02-05 | EFFECT | EFFECT (declared effective) | Aralez Pharmaceuticals Inc. | 9999999995-16-003692 ↗ |
| 2016-02-05 | EFFECT | EFFECT (declared effective) | Aralez Pharmaceuticals Inc. | 9999999995-16-003693 ↗ |
| 2016-02-05 | EFFECT | EFFECT (declared effective) | Aralez Pharmaceuticals Inc. | 9999999995-16-003694 ↗ |
| 2016-04-01 | EFFECT | EFFECT (declared effective) | Aralez Pharmaceuticals Inc. | 9999999995-16-004100 ↗ |
| 2016-04-01 | EFFECT | EFFECT (declared effective) | Aralez Pharmaceuticals Inc. | 9999999995-16-004101 ↗ |
| 2016-04-01 | EFFECT | EFFECT (declared effective) | Aralez Pharmaceuticals Inc. | 9999999995-16-004102 ↗ |
| 2016-04-01 | EFFECT | EFFECT (declared effective) | Aralez Pharmaceuticals Inc. | 9999999995-16-004112 ↗ |
| 2017-03-21 | RW | RW (withdrawal request) | Aralez Pharmaceuticals Inc. | 0001104659-17-018361 ↗ |
| 2017-11-22 | EFFECT | EFFECT (declared effective) | Aralez Pharmaceuticals Inc. | 9999999995-17-003054 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2016-01-22 | S-1/A | registration statement | 4,800,000 | - | Nasdaq POZN | 0 | primary document; shares headline | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Aryeh Jason | Director | 5 | 2016–2017 | ||
| QLT INC/BC | TenPercentOwner | 2 | 2016 | ||
| BARNHARDT JOHN E | Officer | VP, Finance & Administration; VP, Finance and Administration | 2 | 2016 | person page Fuzzy |
| Harris Robert Paul | Director | 5 | 2016–2017 | ||
| Kirsch Arthur S | Director | 9 | 2016–2017 | ||
| thrasher francis martin | Director | 4 | 2016–2017 | ||
| ADAMS ADRIAN | Director,Officer | Chief Executive Officer | 4 | 2016–2017 | |
| Armstrong Jennifer Lou | Officer | EVP HR and Administration | 5 | 2016–2017 | |
| Charles Scott J | Officer | Chief Financial Officer | 7 | 2016–2017 | |
| Fowler Neal Franklin | Director | 4 | 2016–2017 | ||
| Glickman Mark A | Officer | Chief Commercial officer; Chief Commercial Officer | 7 | 2016–2018 | |
| KOVEN ANDREW I | Officer | President & CBO; President & Chief Business Off | 11 | 2016–2018 | |
| LEE KENNETH B JR | Director | 7 | 2016–2017 | ||
| RUDNICK SETH | Director | 6 | 2016–2017 | ||
| Trachtenberg Eric | Officer | GC, CCO & Secretary; GC, COO & Secretary; General Counsel, COO & Sect | 7 | 2016–2018 | |
| Tursi James Patrick | Officer | Chief Medical Officer | 10 | 2016–2018 | |
| Kaseta Michael | Officer | Chief Financial Officer; Interim CFO | 3 | 2017–2018 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2016-02-19 | Aralez Pharmaceuticals Inc. | Pharmaceuticals | $75,000,000 | $75,000,000 | 3 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Aralez Pharmaceuticals Inc. | Form D private offerings | CIK (EXACT) | |
| SEC filer | Aralez Pharmaceuticals Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | John E Barnhardt | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, A1 first:
- ONCOGENEX TECHNOLOGIES INC A1
- Aspreva Pharmaceuticals CORP A1
- Lexaria Bioscience Corp. A1
- Zymeworks BC Inc. A1
- BetterLife Pharma Inc. A1
- ABATTIS BIOCEUTICALS CORP A1
- BriaCell Therapeutics Corp. A1
- AbCellera Biologics Inc. A1
- BODY & MIND INC. A1
- XORTX Therapeutics Inc. A1
In other datasets, the same topic (Health) in A1:
- Form D issuer: 1219014 B.C. Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health